182 related articles for article (PubMed ID: 35008835)
1. Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS).
Xie X; Frank D; Patnana PK; Schütte J; Al-Matary Y; Liu L; Wei L; Dugas M; Varghese J; Nimmagadda SC; Khandanpour C
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008835
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML.
Botezatu L; Michel LC; Helness A; Vadnais C; Makishima H; Hönes JM; Robert F; Vassen L; Thivakaran A; Al-Matary Y; Lams RF; Schütte J; Giebel B; Görgens A; Heuser M; Medyouf H; Maciejewski J; Dührsen U; Möröy T; Khandanpour C
Exp Hematol; 2016 Aug; 44(8):713-726.e14. PubMed ID: 27216773
[TBL] [Abstract][Full Text] [Related]
3. Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.
Frank D; Patnana PK; Vorwerk J; Mao L; Gopal LM; Jung N; Hennig T; Ruhnke L; Frenz JM; Kuppusamy M; Autry R; Wei L; Sun K; Mohammed Ahmed HM; Künstner A; Busch H; Müller H; Hutter S; Hoermann G; Liu L; Xie X; Al-Matary Y; Nimmagadda SC; Cano FC; Heuser M; Thol F; Göhring G; Steinemann D; Thomale J; Leitner T; Fischer A; Rad R; Röllig C; Altmann H; Kunadt D; Berdel WE; Hüve J; Neumann F; Klingauf J; Calderon V; Opalka B; Dührsen U; Rosenbauer F; Dugas M; Varghese J; Reinhardt HC; von Bubnoff N; Möröy T; Lenz G; Batcha AMN; Giorgi M; Selvam M; Wang E; McWeeney SK; Tyner JW; Stölzel F; Mann M; Jayavelu AK; Khandanpour C
Blood; 2023 Dec; 142(25):2175-2191. PubMed ID: 37756525
[TBL] [Abstract][Full Text] [Related]
4. GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome.
Botezatu L; Michel LC; Makishima H; Schroeder T; Germing U; Haas R; van der Reijden B; Marneth AE; Bergevoet SM; Jansen JH; Przychodzen B; Wlodarski M; Niemeyer C; Platzbecker U; Ehninger G; Unnikrishnan A; Beck D; Pimanda J; Hellström-Lindberg E; Malcovati L; Boultwood J; Pellagatti A; Papaemmanuil E; Le Coutre P; Kaeda J; Opalka B; Möröy T; Dührsen U; Maciejewski J; Khandanpour C
Exp Hematol; 2016 Jul; 44(7):590-595.e1. PubMed ID: 27080012
[TBL] [Abstract][Full Text] [Related]
5. GFI1 as a novel prognostic and therapeutic factor for AML/MDS.
Hönes JM; Botezatu L; Helness A; Vadnais C; Vassen L; Robert F; Hergenhan SM; Thivakaran A; Schütte J; Al-Matary YS; Lams RF; Fraszscak J; Makishima H; Radivoyevitch T; Przychodzen B; da Conceição Castro SV; Görgens A; Giebel B; Klein-Hitpass L; Lennartz K; Heuser M; Thiede C; Ehninger G; Dührsen U; Maciejewski JP; Möröy T; Khandanpour C
Leukemia; 2016 Jun; 30(6):1237-45. PubMed ID: 26847026
[TBL] [Abstract][Full Text] [Related]
6. A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia.
Khandanpour C; Thiede C; Valk PJ; Sharif-Askari E; Nückel H; Lohmann D; Horsthemke B; Siffert W; Neubauer A; Grzeschik KH; Bloomfield CD; Marcucci G; Maharry K; Slovak ML; van der Reijden BA; Jansen JH; Schackert HK; Afshar K; Schnittger S; Peeters JK; Kroschinsky F; Ehninger G; Lowenberg B; Dührsen U; Möröy T
Blood; 2010 Mar; 115(12):2462-72. PubMed ID: 20075157
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis.
Khandanpour C; Eisfeld C; Nimmagadda SC; Raab MS; Weinhold N; Seckinger A; Hose D; Jauch A; Försti A; Hemminki K; Hielscher T; Hummel M; Lenz G; Goldschmidt H; Huhn S
Front Oncol; 2021; 11():757664. PubMed ID: 34760702
[TBL] [Abstract][Full Text] [Related]
8. Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic Implications.
Möröy T; Khandanpour C
Front Oncol; 2019; 9():824. PubMed ID: 31508375
[TBL] [Abstract][Full Text] [Related]
9. Presence of the
Vorwerk J; Sun K; Frank D; Neumann F; Hüve J; Budde PM; Liu L; Xie X; Patnana PK; Ahmed HMM; Opalka B; Lenz G; Jayavelu AK; Khandanpour C
Front Oncol; 2022; 12():903691. PubMed ID: 36003783
[TBL] [Abstract][Full Text] [Related]
10. Dose-dependent expression of GFI1 alters metabolism in the haematopoietic progenitors and MLL::AF9-induced leukaemic cells.
Patnana PK; Liu L; Frank D; Nimmagadda SC; Behrens M; Ahmed H; Xie X; Liebmann M; Wei L; Gerdemann A; Thivakaran A; Humpf HU; Klotz L; Dugas M; Varghese J; Trajkovic-Arsic M; Siveke JT; Hanenberg H; Opalka B; Dührsen U; Reinhardt HC; Guenther U; von Bubnoff N; Khandanpour C
Br J Haematol; 2023 Sep; 202(5):1033-1048. PubMed ID: 37423893
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of high GFI1 expression in AML of normal karyotype and its association with a FLT3-ITD signature.
Volpe G; Walton DS; Grainger DE; Ward C; Cauchy P; Blakemore D; Coleman DJL; Cockerill PN; Garcia P; Frampton J
Sci Rep; 2017 Sep; 7(1):11148. PubMed ID: 28894287
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
Zhao X; Tian X; Kajigaya S; Cantilena CR; Strickland S; Savani BN; Mohan S; Feng X; Keyvanfar K; Dunavin N; Townsley DM; Dumitriu B; Battiwalla M; Rezvani K; Young NS; Barrett AJ; Ito S
Br J Haematol; 2016 Nov; 175(3):427-439. PubMed ID: 27433923
[TBL] [Abstract][Full Text] [Related]
13. Enforced GFI1 expression impedes human and murine leukemic cell growth.
Hönes JM; Thivakaran A; Botezatu L; Patnana P; Castro SVDC; Al-Matary YS; Schütte J; Fischer KBI; Vassen L; Görgens A; Dührsen U; Giebel B; Khandanpour C
Sci Rep; 2017 Nov; 7(1):15720. PubMed ID: 29147018
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of growth factor independence 1 expression in patients with
Salarpour F; Goudarzipour K; Mohammadi MH; Ahmadzadeh A; Faraahi S; Allahbakhshian A; Farsani MA
J Cancer Res Ther; 2020; 16(1):23-27. PubMed ID: 32362605
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia.
Wong JJ; Lau KA; Pinello N; Rasko JE
Cancer Sci; 2014 Nov; 105(11):1457-63. PubMed ID: 25220401
[TBL] [Abstract][Full Text] [Related]
17. miRNA-650 exerts anti-leukemia activity by inhibiting cell proliferation through Gfi1 targeting.
Yuan C; Xu L; Du P; Pang J
Tumori; 2018 Oct; 104(5):369-374. PubMed ID: 28574132
[TBL] [Abstract][Full Text] [Related]
18. SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS.
Chen BY; Song J; Hu CL; Chen SB; Zhang Q; Xu CH; Wu JC; Hou D; Sun M; Zhang YL; Liu N; Yu PC; Liu P; Zong LJ; Zhang JY; Dai RF; Lan F; Huang QH; Zhang SJ; Nimer SD; Chen Z; Chen SJ; Sun XJ; Wang L
Blood; 2020 Jun; 135(25):2271-2285. PubMed ID: 32202636
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.
Liu HB; Urbanavicius D; Tan P; Spencer A; Dear AE
Int J Oncol; 2014 Oct; 45(4):1742-8. PubMed ID: 25051119
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
